Targeting ACSL4, either genetically or pharmacologically, significantly reduced muscle cell death and rhabdomyolysis biomarkers both in vitro and in vivo, suggesting ACSL4 inhibition is a promising therapeutic strategy to prevent EHS-induced rhabdomyolysis (He et al., 2022). This evidence concerns the gene ACSL4 and rhabdomyolysis.